Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
22. lappuse
... paragraph ( c ) ( 1 ) ( i ) of this section is not required to submit a 15 - day " Alert report " for an adverse drug experience obtained from a postmarketing study ( whether or not conducted under an investiga- tional new drug ...
... paragraph ( c ) ( 1 ) ( i ) of this section is not required to submit a 15 - day " Alert report " for an adverse drug experience obtained from a postmarketing study ( whether or not conducted under an investiga- tional new drug ...
23. lappuse
... paragraph ( a ) ; by re- vising paragraphs ( b ) , ( c ) , ( d ) ( 1 ) , ( d ) ( 3 ) ( ii ) , and ( d ) ( 4 ) ; by removing in paragraph ( d ) ( 2 ) , the introductory text of paragraph ( d ) ( 3 ) , and paragraph ( d ) ( 3 ) ( i ) the ...
... paragraph ( a ) ; by re- vising paragraphs ( b ) , ( c ) , ( d ) ( 1 ) , ( d ) ( 3 ) ( ii ) , and ( d ) ( 4 ) ; by removing in paragraph ( d ) ( 2 ) , the introductory text of paragraph ( d ) ( 3 ) , and paragraph ( d ) ( 3 ) ( i ) the ...
24. lappuse
... paragraph ( c ) ( 1 ) ( 1 ) of this section is not required to sub- mit a 15 - day " Alert report " for an adverse drug experience obtained from a post- marketing study ( whether or not conducted under an investigational new drug ...
... paragraph ( c ) ( 1 ) ( 1 ) of this section is not required to sub- mit a 15 - day " Alert report " for an adverse drug experience obtained from a post- marketing study ( whether or not conducted under an investigational new drug ...
26. lappuse
... paragraph ( a ) ( 1 ) ( vii ) of this section and / or to comply with all of the certifi- cation requirements of paragraph ( a ) ( 3 ) of this section shall be justification for withdrawal of approval of the applica- tion under section ...
... paragraph ( a ) ( 1 ) ( vii ) of this section and / or to comply with all of the certifi- cation requirements of paragraph ( a ) ( 3 ) of this section shall be justification for withdrawal of approval of the applica- tion under section ...
36. lappuse
... paragraph ( c ) of this section , in the " chemical form ” and intended for the uses stated , is ter- minated on March 3 , 1972 , except as provided in paragraph ( d ) ( 3 ) of this sec- tion . ( 3 ) The exemption referred to in para ...
... paragraph ( c ) of this section , in the " chemical form ” and intended for the uses stated , is ter- minated on March 3 , 1972 , except as provided in paragraph ( d ) ( 3 ) of this sec- tion . ( 3 ) The exemption referred to in para ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning